article thumbnail

STAT+: Belgian anti-trust authorities probe Roche for allegedly delaying biosimilars of two cancer meds

STAT

Belgian anti-trust regulators are probing Roche over concerns that the drug company took steps to delay the entry of biosimilar versions of two of its cancer medicines. The agency also maintained Roche disseminated “erroneous information” about using biosimilars in combination therapy.

article thumbnail

Steep drop for UK industry clinical trials between 2017 and 2021

European Pharmaceutical Review

The number of industry clinical trials initiated in the UK, per year, fell by 41 percent from 2017 to 2021, according to the latest annual report on clinical research from the Association of the British Pharmaceutical Industry ( ABPI ). million people living with rare diseases in the UK.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innoviva enters agreement to acquire La Jolla Pharmaceutical Company

Pharmaceutical Technology

Innoviva has signed a definitive merger agreement for the acquisition of all of the outstanding shares of La Jolla Pharmaceutical Company for $6.23 The lead product of the company, Giapreza (angiotensin II) obtained the Food and Drug Administration (FDA) approval in December 2017.

article thumbnail

STAT+: AbbVie dramatically outspent its pharma company rivals in 2023 to promote its drugs to doctors

STAT

WASHINGTON — Pharmaceutical giant AbbVie paid health care providers roughly $145.7 The massive sum spent by AbbVie, the maker of the mega blockbuster anti-inflammatory drug Humira, is the most a pharmaceutical company has spent on marketing to doctors since such data became available in 2017.

article thumbnail

Pharmaceutical training boost: how the growth and skills levy could shape industry development

European Pharmaceutical Review

The Association of the British Pharmaceutical Industry (ABPI) has welcomed the proposed changes, highlighting their potential to support talent development in areas such as advanced manufacturing, digital skills, and emerging biotechnologies. billion in 2017/18 to 2.5 billion in 2023/24.

article thumbnail

STAT+: Teva agrees to pay $450 million to settle kickback and price-fixing allegations

STAT

Separately, the drugmaker agreed to pay $25 million to settle charges of participating in a price-fixing scheme with other generic companies. At the same time, Teva steadily raised the price of its drug by thousands of dollars. At the same time, Teva steadily raised the price of its drug by thousands of dollars.

article thumbnail

STAT+: Icon acquires HumanFirst to boost support for digital tools in clinical trials

STAT

As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired HumanFirst, which helps companies answer exactly those sorts of questions.